EGb 761® in vMCI, MCI and dementia prevention
|
Non-demented patients |
EGb 761® or Piracetam and placebo, data collected on cognitive function over a period of twenty years |
Patients treated with EGb 761® highlighted a slower cognitive impairment than in Piracetam group. Moreover, EGb 761® patients showed a significant reduction of psychotropic drugs assumption. |
[90] |
Patients with very mild cognitive impairment and low functioning |
EGb 761® (240 mg/die) or placebo, for 12 weeks |
Patients treated with EGb 761® showed an improvement of memory performances, measured through Wechsler Memory Scale III (human face recognition in pictures) and a significant attention improvement, by using the Vienna Test System Work Performance Series (a computerized math test to keep concentration). |
[91] |
EGb 761® MCI, neurocognitive deficit and dementia
|
Patients with amnesic MCI |
EGb 761® (240 mg/die) or placebo, for 24 weeks |
Patients treated with EGb 761® showed improvement in all the neuropsychiatric symptoms, measured through Neuropsychiatrics Inventory (NPI) sympoms. |
[94] |
Patients with normal cognitive function or MCI |
EGb 761® (240 mg/die) or placebo, patients were evaluated every 6 months |
This study didn’t demonstrate any significant benefit to prevent dementia development with EGb 761® treatment versus placebo. |
[95] |
Outpatients with mild to moderate dementia (AD or VaD) |
EGb 761® (240 mg/die) or placebo, for 24 weeks |
Patients treated with EGb 761® demonstrated neuro psychiatric improvement for Neuropsychiatric Inventory (NPI) symptoms. |
[96] |
Outpatients 24-week with mild to moderate dementia (Alzheimer’s disease or vascular dementia) associated with neuropsychiatric symptoms |
EGb 761® (240 mg/die) or placebo, for 24 weeks |
Treatment with EGb 761® led to a significant and clinically relevant improvement in patients’ cognition, psychopathology, functional measures and quality of life. |
[97] |